Table 1 |.

Approved immune checkpoint inhibitors and indications

Currently approved immune checkpoint inhibitors

PD-1 inhibitors

Pembrolizumab (Keytruda)

Nivolumab (Opdivo)

PD-ligand 1 inhibitors

Atezolizumab (Tecentriq)

Avelumab (Bavencio)

Durvalumab (Imfinzi)

CTLA-4 inhibitor

Ipilimumab (Yervoy)

Currently approved indications

Renal cell carcinoma

Urothelial cell carcinoma

Non-small cell carcinoma

Metastatic melanoma

Hodgkin’s lymphoma

Head and neck cancer

Hepatocellular cancer

Stomach cancer

Merkel cell carcinoma

Any solid tumor with positive biomarkers (i.e., microsatellite and genetic instability)